NASDAQ · PHVS
Pharvaris N.V.
$33.58+$0.76 (+2.32%)
Pharvaris N.V.’s quoted price sits in the upper half of its reported 52-week range, 22.36% below the high.
Loading market information…
NYSE · TDOC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Teladoc Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Teladoc Health, Inc.’s next earnings report is currently expected on Feb 24, 2027, with estimated earnings per share of -$0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Teladoc Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:47 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 29, 2025 | -$0.19+29.63% vs estimate | $631.90M+1.5% vs estimate |
|---|
| Q1 2025 | Apr 30, 2025 | -$0.53-60.61% vs estimate | $629.37M+1.64% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.28-21.74% vs estimate | $640.49M+0.15% vs estimate |
|---|
THE ANALYST VIEW
42 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $8.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$33.58+$0.76 (+2.32%)
Pharvaris N.V.’s quoted price sits in the upper half of its reported 52-week range, 22.36% below the high.
$29.99-$0.88 (-2.85%)
Schrödinger, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.22% below the high.
$28.40+$0.53 (+1.9%)
Progyny, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.12% below the high.
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
$41.27+$0.64 (+1.58%)
Azenta, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.08% below the high.
$36.88+$0.93 (+2.59%)
Omnicell, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.95% below the high.
$13.11-$1.06 (-7.48%)
Novocure Ltd’s quoted price sits in the lower half of its reported 52-week range, 38.88% below the high.
$19.65+$0.47 (+2.45%)
Omada Health’s quoted price sits in the upper half of its reported 52-week range, 24.8% below the high.
